NCT06063486View on ClinicalTrials.gov

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Clonal Cytopenia of Undetermined SignificanceEssential ThrombocythemiaMyelodysplastic SyndromeMyelofibrosisPolycythemia Vera
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DIETARY_SUPPLEMENT

Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement

Given PO

DIETARY_SUPPLEMENT

Piperine Extract (Standardized)

Given PO

DRUG

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER